Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1994 1
1995 2
2019 1
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Hagström E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Hagström E, et al. Circulation. 2022 Aug 30;146(9):657-672. doi: 10.1161/CIRCULATIONAHA.121.057807. Epub 2022 Jun 30. Circulation. 2022. PMID: 35770629 Free PMC article. Clinical Trial.
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Ray KK, et al. Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. Lancet Diabetes Endocrinol. 2019. PMID: 31272931 Free article. Clinical Trial.
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, López-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD, Gabriel Steg P; ODYSSEY Outcomes Committees and Investigators. Schwartz GG, et al. J Am Coll Cardiol. 2021 Aug 3;78(5):421-433. doi: 10.1016/j.jacc.2021.04.102. J Am Coll Cardiol. 2021. PMID: 34325831 Free PMC article. Clinical Trial.
[Parkinson disease and the neuronal dopamine uptake complex].
Costentin J. Costentin J. Ann Pharm Fr. 1995;53(4):145-54. Ann Pharm Fr. 1995. PMID: 7574268 Review. French.
It is involved in the uptake of the dopamine released into the synaptic cleft. Considered at the level of nigro-striatal dopaminergic neurons, whose degeneration is responsible for the Parkinson's disease, this carrier seems to constitute a major target. It could be involv …
It is involved in the uptake of the dopamine released into the synaptic cleft. Considered at the level of nigro-striatal dopaminergic …
Short-term treatments with haloperidol or bromocriptine do not alter the density of the monoamine vesicular transporter in the substantia nigra.
Naudon L, Leroux-Nicollet I, Costentin J. Naudon L, et al. Neurosci Lett. 1994 May 23;173(1-2):1-4. doi: 10.1016/0304-3940(94)90136-8. Neurosci Lett. 1994. PMID: 7523993
Thus, it appears that these pharmacological modifications, imposed to the activity of the nigro-striatal dopaminergic system during 2 days, have no consequence on the rate of synthesis of its vesicles....
Thus, it appears that these pharmacological modifications, imposed to the activity of the nigro-striatal dopaminergic system during 2 …
Consequences of an intrastriatal injection of kainic acid on the dopaminergic neuronal and vesicular uptake systems.
Naudon L, Leroux-Nicollet I, Costentin J. Naudon L, et al. Brain Res. 1992 Oct 9;593(1):32-8. doi: 10.1016/0006-8993(92)91259-h. Brain Res. 1992. PMID: 1360863
Intrastriatal kainic acid injection destroys the neurons originating from the striatum, including those on which terminals of the nigro- and meso-striatal dopaminergic neurons project. We have studied at various times the consequences of this lesion on dopamine metabolism …
Intrastriatal kainic acid injection destroys the neurons originating from the striatum, including those on which terminals of the nigro …